Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12622090 | 0.88 | ALDH1A1 (0.49) | HCRTR1HCRTR2MAPTKMT2AALDH1A1 | |
| SCHEMBL13035914 | 0.84 | HCRTR1 (0.50) | HCRTR1HCRTR2MAPTKMT2AALDH1A1 | |
| SCHEMBL12626117 | 0.80 | L3MBTL1 (0.50) | HCRTR1HCRTR2KMT2AALDH1A1MEN1 | |
| SCHEMBL23160004 | 0.77 | ALDH1A1 (0.51) | HCRTR1HCRTR2KMT2AALDH1A1MEN1 | |
| SCHEMBL12626946 | 0.77 | HCRTR1 (0.53) | HCRTR1HCRTR2ALDH1A1L3MBTL1LMNA | |
| SCHEMBL23159676 | 0.74 | L3MBTL1 (0.60) | HCRTR1HCRTR2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL25493754 | 0.73 | L3MBTL1 (0.52) | HCRTR1HCRTR2ALDH1A1L3MBTL1 | |
| SCHEMBL12656080 | 0.73 | ALDH1A1 (0.46) | MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL12623977 | 0.72 | HCRTR1 (0.51) | HCRTR1HCRTR2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL12623972 | 0.72 | ALDH1A1 (0.47) | HCRTR1HCRTR2MAPTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580809-B2 | Filamin A-binding anti-inflammatory analgesic | PAIN THERAPEUTICS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | FLNA, FLNB, OPRK1 | HCRTR1 3537/4885HCRTR2 3420/4885MAPT 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.